Hansa Biopharma AB (publ) (LON:0RC7)

Market Cap	113.91M
Revenue (ttm)	12.36M
Net Income (ttm)	-58.23M
Shares Out	n/a
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,097
Average Volume	42,203
Open	23.75
Previous Close	23.64
Day's Range	22.72 - 23.78
52-Week Range	45.06 - 105.70
Beta	1.41
RSI	26.85
Earnings Date	Feb 6, 2025

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 135
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RC7

Financial Performance

In 2024, Hansa Biopharma AB's revenue was 171.32 million, an increase of 27.76% compared to the previous year's 134.09 million. Losses were -806.74 million, -3.00% less than in 2023.

Financial numbers in SEK